GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DT&CRO Co Ltd (XKRX:383930) » Definitions » Capex-to-Revenue

DT&CRO Co (XKRX:383930) Capex-to-Revenue : 0.54 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is DT&CRO Co Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

DT&CRO Co's Capital Expenditure for the three months ended in Mar. 2024 was ₩-3,561.44 Mil. Its Revenue for the three months ended in Mar. 2024 was ₩6,579.29 Mil.

Hence, DT&CRO Co's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.54.


DT&CRO Co Capex-to-Revenue Historical Data

The historical data trend for DT&CRO Co's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DT&CRO Co Capex-to-Revenue Chart

DT&CRO Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
0.15 0.25 0.34 0.64

DT&CRO Co Quarterly Data
Jun21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.57 0.57 0.41 4.62 0.54

Competitive Comparison of DT&CRO Co's Capex-to-Revenue

For the Biotechnology subindustry, DT&CRO Co's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DT&CRO Co's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DT&CRO Co's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where DT&CRO Co's Capex-to-Revenue falls into.



DT&CRO Co Capex-to-Revenue Calculation

DT&CRO Co's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-17056.396) / 26586.277
=0.64

DT&CRO Co's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-3561.442) / 6579.29
=0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DT&CRO Co  (XKRX:383930) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


DT&CRO Co Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of DT&CRO Co's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


DT&CRO Co (XKRX:383930) Business Description

Traded in Other Exchanges
N/A
Address
28, Baengnyeong-ro 20beon-gil, 2nd, 3rd, 4th floor, Na-dong, Cheoin-gu, Gyeonggi-do (Yubang-dong), Yongin-si, KOR, 17042
DT&CRO Co Ltd conducts a series of consigned research, from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional foods, cosmetics and medical devices, to analysis, bioactivity, clinical trials, and licensing consulting. provided as a service.

DT&CRO Co (XKRX:383930) Headlines

No Headlines